A new injectable formulation of Keytruda, a leading cancer immunotherapy, is set to revolutionise treatment for thousands of NHS patients across the UK, significantly reducing their time spent in hospital. This innovative delivery method promises to streamline the administration of the drug, which has been a mainstay in cancer therapy since its introduction in 2015.
Faster Treatment for Cancer Patients
Keytruda, also known as pembrolizumab, has been widely used to treat various types of cancer, including lung, breast, and cervical cancer. Traditionally, patients have received the medication through an intravenous infusion that could take over an hour. However, NHS England has announced that the new injection will allow the same treatment to be delivered in just a couple of minutes, greatly benefiting both patients and healthcare professionals.
Shirley Xerxes, an 86-year-old from St Albans, Hertfordshire, was among the first recipients of this new injectable treatment at the Mount Vernon Cancer Centre. She expressed her gratitude, stating, “I was in the chair for a matter of minutes instead of an hour or more. It’s made such a difference and gives me more time to live my life, including spending more time gardening.”
Approximately 14,000 patients in England commence a course of Keytruda each year, with many expected to transition to this more efficient injectable version. The injection will be administered every three weeks for most patients, with some requiring treatment every six weeks depending on their specific cancer diagnosis.
The Science Behind Immunotherapy
Immunotherapy represents a groundbreaking approach to cancer treatment. It harnesses the body’s immune system to identify and destroy cancer cells, which often disguise themselves using proteins that signal the immune system to refrain from attacking. This “invisibility cloak” tactic is countered by immunotherapy, enabling the immune system to recognise and combat these malignant cells.
Keytruda has been pivotal in this field, gaining approval for various cancer types since its initial use for skin cancer. Its success has led to it becoming one of the most widely prescribed medications globally, with estimated sales reaching $30 billion (£22 billion) by 2025. The drug’s development was recognised with a Nobel Prize for Medicine in 2018, awarded to scientists James Allison and Tasuku Honjo for their contributions to immunotherapy principles.
Transforming Cancer Care
The introduction of this injectable form of Keytruda is not just about convenience; it also holds the potential to alleviate pressure on NHS resources. By shortening the time required for drug administration, healthcare facilities can manage patient flow more effectively. Professor Peter Johnson, NHS England’s National Clinical Director for Cancer, emphasised the significance of this change: “Managing cancer treatment and regular hospital trips can be really exhausting. If we can do this in a much shorter period of time, it frees up space in our chemotherapy units and means we can start thinking about giving treatment in the community and away from hospitals.”
While the exact costs associated with this new formulation remain undisclosed due to a confidential agreement with the drug manufacturer Merck Sharp & Dohme (MSD), it is believed that the NHS will pay a comparable price for both injectable and infusion forms of Keytruda. The patent for the original formulation is set to expire in the coming years, paving the way for potential competition from generic versions of the drug.
Why it Matters
This development in cancer treatment signifies a monumental shift towards more patient-centric care, reducing the burden of lengthy hospital visits and enhancing the overall quality of life for patients. As the NHS continues to adapt to the needs of its patients, innovations like the injectable Keytruda not only promise improved treatment efficiency but also represent a step toward making cancer care more accessible and manageable for those facing this challenging diagnosis.
